drugset
drugset / Trial / NCT05298423

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

NCT05298423 ↗

Phase 3 Active not recruiting 611 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupSingle-blindTreatment

Summary

Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.

Timeline

Start
2022-05-03
Primary completion
2026-06-15
Completion
2026-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 10 mg/kg Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Vibostolimab Monoclonal antibody 200 mg Intravenous
Background Carboplatin Small molecule 2 unknown Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Cisplatin Other / unclassified 50 mg/m2 Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Etoposide Small molecule 50 mg/m2 Intravenous
Background Paclitaxel Small molecule 45 mg/m2 Intravenous
Background Paclitaxel Small molecule 200 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma